Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home Medicines & Healthy Lifestyle

Oral Glycogen Synthase Inhibitor Designated Orphan Drug for Pompe Disease

admin by admin
September 5, 2022
in Medicines & Healthy Lifestyle


The Food and Drug Administration (FDA) has granted Orphan Drug designation to MZE001 for the treatment of Pompe disease.

Pompe disease is a rare, degenerative muscle disorder caused by mutations in the acid alpha-glucosidase gene, which leads to the abnormal buildup of glycogen in tissues and subsequent organ impairment. 

MZE001 is an oral glycogen synthase (GYS1) inhibitor designed to limit the buildup of disease-causing glycogen through substrate reduction therapy. The Company is currently investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of MZE001 in healthy volunteers in a phase 1 study (ClinicalTrials.gov Identifier: NCT05249621).


Continue Reading

“We are pleased to have received this designation from the FDA for MZE001, which underscores the need for new, innovative treatments for Pompe disease,” said Jason Coloma, PhD, CEO of Maze. “MZE001 is a novel mechanism we believe could be beneficial both as a monotherapy for late-onset patients as well as complement to enzyme replacement therapies across the disease spectrum.”

The FDA’s Orphan Drug designation is granted to medicines intended to treat or prevent rare diseases or disorders that affect fewer than 200,000 individuals. 

Reference

Maze Therapeutics announces FDA Orphan Drug designation granted to MZE001 for the treatment of Pompe disease. News release. Maze Therapeutics, Inc. Accessed August 31, 2022. https://www.businesswire.com/news/home/20220831005268/en/Maze-Therapeutics-Announces-FDA-Orphan-Drug-Designation-Granted-to-MZE001-for-the-Treatment-of-Pompe-Disease

This article originally appeared on MPR

Topics:

Inborn Errors Of Metabolism
Metabolic Disorders



Source link

Previous Post

E. Coli Outbreak Possibly Linked To Wendy’s Reaches 6 States, Infects Nearly 100

Next Post

Health Bulletin 5/September/2022

Next Post

Health Bulletin 5/September/2022

Recommended

Researchers Identify Ages When People Sleep The Least, And It’s Not Early 20s

December 26, 2022

Pediatricians recommend obesity drugs for children

January 9, 2023

Don't miss it

Pharmaceutical

Strange bedfellows lobby for Medicare obesity-drug coverage

January 26, 2023
Medicines & Healthy Lifestyle

FDA Panel Votes on Rezafungin for Treatment of Candidemia, Invasive Candidiasis

January 26, 2023
Medicines & Healthy Lifestyle

This Cancer Drug Can Increase Longevity, Study Finds

January 26, 2023
News

Something in Breast Milk Helps Protect Babies Against Allergies

January 26, 2023
Pharmaceutical

Merck ends late-stage trial for Keytruda in prostate cancer

January 25, 2023
Medicines & Healthy Lifestyle

Are Seed Oils Behind the Majority of Diseases This Century?

January 25, 2023

© 2022 Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.